Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation
Andrew T.L. Ong, MBBS, FRACP,
Angela Hoye, MBChB, MRCP,
Jiro Aoki, MD,
Carlos A.G. van Mieghem, MD,
Gaston A. Rodriguez Granillo, MD,
Karel Sonnenschein,
Evelyn Regar, MD, PhD,
Eugene P. McFadden, MBChB, MD, FRCPI, FACC,
Georgios Sianos, MD, PhD,
Willem J. van der Giessen, MD, PhD,
Peter P.T. de Jaegere, MD, PhD,
Pim de Feyter, MD, PhD, FACC,
Ron T. van Domburg, PhD and
Patrick W. Serruys, MD, PhD, FACC*
Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
View larger version (18K):
[in a new window]
|
Figure 1 Cumulative incidence of angiographic stent thrombosis stratified by groups against time. Vertical line = day 11 on horizontal axis. BMS = bare-metal stents; PES = paclitaxel-eluting stents; SES = sirolimus-eluting stents.
|
|
|
